Contact
Please use this form to send email to PR contact of this press release:
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
TO:
Please use this form to send email to PR contact of this press release:
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
TO: